Exact Sciences Corporation (EXAS)
$
43.29
-0.37 (-0.85%)
Key metrics
Financial statements
Free cash flow per share
0.4023
Market cap
8.4 Billion
Price to sales ratio
3.0292
Debt to equity
1.1467
Current ratio
3.2532
Income quality
-1.2816
Average inventory
149.7 Million
ROE
-0.3447
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Exact Sciences Corporation specializes in cancer screening and diagnostic test products both in the United States and internationally. The company is renowned for its Cologuard test, a non-invasive stool-based DNA screening method that detects DNA and hemoglobin biomarkers linked to colorectal cancer and pre-cancer. In addition, it offers Oncotype DX, a comprehensive gene expression test utilized for breast, prostate, and colon cancers. The Oncotype Test provides tissue profiling that assists in therapy selection for patients with advanced, metastatic, refractory, or recurrent cancers. Furthermore, the Oncotype DX AR-V7 Nucleus Detect Test serves as a liquid-based diagnostic tool specific to advanced-stage prostate cancer. The Oncomap ExTra test gives a detailed biological assessment for certain refractory, rare, or aggressive cancers. Additionally, Exact Sciences plays a role in providing Covid-19 testing services. The company's ongoing research pipeline is focused on improving the performance characteristics of the Cologuard test while also developing blood and other fluid-based tests. The company's stock is identified with the symbol 'EXAS' in the market. The net income ratio is -0.37 reflecting the company's profitability margin, while the income before tax ratio is -0.37 indicating the pre-tax margin. Exact Sciences earned an interest income of -$5,296,000.00 showcasing its financial investments. The diluted EPS is -$5.59 accounting for potential share dilution. The stock is reasonably priced at $43.15 appealing to a broad range of investors. With a mid-range market capitalization of $8,041,333,950.00 the company is a steady performer in the market. Furthermore, the stock has a high average trading volume of 2,214,951.00 indicating strong liquidity and investor interest. As a key player in the Medical - Diagnostics & Research industry, Exact Sciences contributes significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within the healthcare industry. The emphasis on cancer diagnosis and screening positions the company as an essential entity in the ongoing fight against cancer, ensuring it remains at the forefront of diagnostic advancements and patient care solutions.
What is Exact Sciences Corporation (EXAS)'s stock forecast?
Analysts predict Exact Sciences Corporation stock to fluctuate between $40.62 (low) and $79.62 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Exact Sciences Corporation's market capitalization?
As of 2025-04-01, Exact Sciences Corporation's market cap is $8,041,333,950, based on 185,755,000 outstanding shares.
How does Exact Sciences Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Exact Sciences Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Exact Sciences Corporation (EXAS) stock?
To buy Exact Sciences Corporation (EXAS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EXAS. Place an order (Market, Limit, etc.).
What is the best time to invest in Exact Sciences Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Exact Sciences Corporation perform in the last earnings report?
Revenue: $2,758,867,000 | EPS: -$5.59 | Growth: 394.69%.
Where can I find Exact Sciences Corporation's investor relations reports?
Visit https://www.exactsciences.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Exact Sciences Corporation?
You can explore historical data from here
What is the all-time high and low for Exact Sciences Corporation stock?
All-time high: $158 (2021-02-16) | All-time low: $29.27 (2022-10-13).
What are the key trends affecting Exact Sciences Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd.
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening.
businesswire.com
BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci.
zacks.com
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference, Orlando Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET The webcasts can be acces.
seekingalpha.com
Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core business shows momentum, with strong demand for Cologuard and a solid cash position of $1.04B. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.
seekingalpha.com
Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Catherine Schulte - Baird Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Jack Meehan - Nephron Research Andrew Brackmann - William Blair Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Subu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Dan Leonard - UBS Bill Bonello - Craig Hallum Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research Andrew Cooper - Raymond James Kyle Mikson - Canaccord Operator Good day, everyone, and welcome to the Exact Sciences Fourth Quarter 2024 Earnings Call. Today's call is being recorded.
zacks.com
Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.
zacks.com
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
See all news
